

Hematologic Oncology Update

Volume 9, Issue 3 (Video Program)

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

The treatment of hematologic cancer remains a challenge for many healthcare professionals despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of *Hematologic Oncology Update* features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES

- Consider current and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular, mantle cell and diffuse large B-cell lymphomas.
- Appreciate the recent FDA approvals of several novel therapies for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and discern how these therapies can be appropriately and safely integrated into routine clinical practice.
- Reevaluate current treatment approaches for patients with myeloproliferative disorders and acute and chronic leukemias in light of newly emerging clinical trial data.
- Assess the benefits and risks of evidence-based systemic treatment options to optimize the care of patients with peripheral T-cell lymphoma.
- Consider available research data and other clinical factors in the best-practice selection, sequencing and combining of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory multiple myeloma.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at [ResearchToPractice.com/Privacy-Policy](https://www.researchtopractice.com/Privacy-Policy) for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/HOU316/Video/CME](https://www.researchtopractice.com/HOU316/Video/CME).

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of

interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Sagar Lonial, MD

Professor and Executive Vice Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Advisory Committee and Consulting Agreements:

Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

Loretta J Nastoupil, MD

Assistant Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
Director, Lymphoma Outcomes Database
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, TG Therapeutics Inc; **Consulting Agreement:** Gilead Sciences Inc; **Contracted Research:** Abbott Laboratories, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, TG Therapeutics Inc.

Laurie H Sehn, MD, MPH

Centre for Lymphoid Cancer
BC Cancer Agency and University of British Columbia
Vancouver, British Columbia, Canada

Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Lundbeck, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology, TG Therapeutics Inc.

Raoul Tibes, MD, PhD

Consultant, Mayo Clinic
Assistant Professor of Medicine, Mayo College of Medicine
Scholar in Clinical Research, Leukemia and
Lymphoma Society
Scottsdale, Arizona

Clinical Trial Funding: Astellas Pharma Global Development Inc, Merck, Novartis Pharmaceuticals Corporation.

EDITOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia

Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2017

Expiration date: March 2018

Select Publications

- Ali SA et al. **T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.** *Blood* 2016;128(13):1688-700.
- A phase 3 open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma.** NCT01650701
- Attal M et al. **Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial).** *Proc ASH* 2015;Abstract 391.
- Avet-Loiseau H et al. **Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial.** *Proc ASH* 2015;Abstract 191.
- Bajpai R et al. **Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.** *Oncogene* 2016;35(30):3955-64.
- Byrd JC et al. **Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia.** *N Engl J Med* 2016;374(4):323-32.
- Byrd JC et al; RESONATE Investigators. **Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.** *N Engl J Med* 2014;371(3):213-23.
- Casulo C et al. **T-cell lymphoma: Recent advances in characterization and new opportunities for treatment.** *J Natl Cancer Inst* 2016;109(2):1-9.
- Cheson B et al. **Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: Updated results of the GADOLIN study.** *Proc ASH* 2016;Abstract 615.
- Durie B et al. **Bortezomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): Results of the randomized phase III trial SWOG S0777.** *Proc ASH* 2015;Abstract 25.
- Fowler NH et al. **Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.** *Haematologica* 2015;100(11):e454-7.
- Goede V et al. **Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.** *N Engl J Med* 2014;370(12):1101-10.
- Kumar SK et al. **Venetoclax monotherapy for relapsed/refractory multiple myeloma: Safety and efficacy results from a phase I study.** *Proc ASH* 2016;Abstract 488.
- Kumar SK et al. **Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study.** *Lancet Oncol* 2014;15(13):1503-12.
- Levis MJ et al. **Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).** *Proc ASCO* 2015;Abstract 7003.
- Lonial S et al. **How I treat high risk myeloma.** *Blood* 2015;126(13):1536-43.
- Marcus R et al. **Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: Primary results of the randomized Phase III GALLIUM study.** *Proc ASH* 2016;Abstract 6.
- Matulis SM et al. **Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.** *Leukemia* 2016;30(5):1086-93.
- Moskowitz CH et al; AETHERA Study Group. **Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2015;385(9980):1853-62.
- Omer B et al. **Administration of most closely HLA-matched multivirus-specific T cells for the treatment of EBV, CMV, Adv, HHV6, and BKV post allogeneic hematopoietic stem cell transplant.** *Proc ASH* 2015;Abstract 622.
- Ravandi F et al. **Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.** *Blood* 2013;121(23):4655-62.
- Rollig C et al. **Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial.** *Lancet Oncol* 2015;16(16):1691-9.

Schiller G et al. **Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.** *Proc ASCO 2014;Abstract 7100.*

Sehn L et al. **Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial.** *Lancet Oncol 2016;17(8):1081-93.*

Stone RM et al. **The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (mut): An international prospective randomized (rand)-P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]).** *Proc ASH 2015;Abstract 6.*

Vitolo U et al. **Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: Final results from an open-label, randomized phase 3 study (GOYA).** *Proc ASH 2016;Abstract 470.*